Newsroom

Mallinckrodt plc to Report Fourth Quarter and Full-Year Fiscal 2014 Results on November 19, 2014

DUBLIN--(BUSINESS WIRE)--Oct. 20, 2014-- Mallinckrodt plc (NYSE: MNK) will report fourth quarter and full-year fiscal 2014 results on November 19, 2014. The company will hold a conference call for investors beginning at 8:30 a.m. U.S. Eastern Time.

The call can be accessed in three ways:

• At the Mallinckrodt website: http://www.mallinckrodt.com/investor_relations/.

• By telephone: For both “listen-only” participants and those who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is (877) 359-9508. For participants outside the U.S., the dial-in number is (224) 357-2393. All callers will be required to provide the Conference ID of 19935233.

• Through an audio replay: A replay of the call will be available beginning Wednesday afternoon, November 19, 2014, and ending at 11:59 p.m. U.S. Eastern Time on November 26, 2014. The dial-in numbers for U.S. participants are (855) 859-2056 or (800) 585-8367. For participants outside the U.S., the replay dial-in number is (404) 537-3406. All callers will be required to provide the Conference ID of 19935233.

ABOUT MALLINCKRODT:

Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology and pulmonology along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients, and the Global Medical Imaging segment include contrast media and nuclear imaging agents. Mallinckrodt has more than 5,500 employees worldwide and a commercial presence in roughly 65 countries. The company's fiscal 2013 revenue totaled $2.2 billion. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Source: Mallinckrodt

Mallinckrodt
John Moten, 314-654-6650
Vice President, Investor Relations
john.moten@mallinckrodt.com
or
Rhonda Sciarra, 314-654-8618
Manager, Communications
rhonda.sciarra@mallinckrodt.com
or
Meredith Fischer, 314-654-3318
Senior Vice President, Communications
meredith.fischer@mallinckrodt.com